房颤抗凝后出血与新发恶性肿瘤诊断:基于人群的队列研究
结果显示21.8%患者发生出血,4.9%新诊断恶性肿瘤,出血与癌症诊断风险显著升高相关(HR 4.0,95%CI 3.8-4.3),且出血后诊断的癌症分期更早。
要点
- 房颤抗凝后出血与随后新发癌症诊断风险升高约4倍相关。
- 消化道、泌尿生殖道出血与对应部位癌症风险关联更强。
- 出血后诊断的癌症分期更早,提示应及时排查而非仅视为抗凝副作用。
核心结论
- 在房颤抗凝患者中,出血与新发癌症诊断强烈相关,且出血后癌症诊断分期更早。
主要发现
- 出血与癌症诊断风险升高相关,HR为4.0(95%CI 3.8-4.3)。
- 按出血部位,消化道HR 5.0(95%CI 4.6-5.5),泌尿生殖道HR 5.0(95%CI 4.4-5.7),呼吸道HR 4.0(95%CI 3.5-4.6),颅内HR 1.8(95%CI 1.4-2.2),鼻咽HR 1.5(95%CI 1.2-2.0)。
- 与出血部位一致的癌症HR更高:消化道15.4,泌尿生殖道11.8,呼吸道10.1。
- 出血后诊断的癌症中Stage 4占27.6%,无出血者为31.3%(P=0.029)。
临床怎么用
- 房颤抗凝后新发出血应视为潜在恶性肿瘤信号,及时进行针对性排查。
- 尤其消化道、泌尿生殖道或呼吸道出血,需警惕对应部位癌症。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bleeding after starting anticoagulation for atrial fibrillation (AF) may be the first sign of malignancy, especially in elderly individuals. There are no recommendations to guide investigations for malignancy after new-onset bleeding after anticoagulation for AF. Our objective was to determine the association of bleeding after starting oral anticoagulation for AF with new diagnoses of malignancy in a population-wide sample. METHODS: We conducted a population-based cohort study using linked administrative data sets of people ≥66 years of age who newly initiated warfarin or direct oral anticoagulants after diagnosis with AF between 2008 and 2022. Follow-up was 2 years after starting anticoagulation. We excluded patients with valvular disease, chronic dialysis, venous thromboembolism, previous cancer, or previously documented bleeding. Bleeding was identified from hospital/emergency department discharge records and physician billings, then handled as a time-varying covariate in cause-specific regression models while adjusting for baseline characteristics. The primary outcome was incident malignancy. We also determined the site of origin of the malignancy and the stage at diagnosis if indicated in the Ontario Cancer Registry. Analyses were repeated while limiting the exposure to specific bleeding sites. RESULTS: Among 119 480 people (mean age, 77.4 years; 52% men) who started anticoagulants, 26 037 (21.8%) had documented bleeding, and 5800 (4.9%) were diagnosed with malignancy within the next 2 years. Bleeding was associated with a higher hazard of cancer diagnosis with a hazard ratio (HR) of 4.0 (95% CI, 3.8-4.3). The HRs for any malignancy were 5.0 (95% CI, 4.6-5.5) for gastrointestinal, 5.0 (95% CI, 4.4-5.7) for genitourinary, 4.0 (95% CI, 3.5-4.6) for respiratory, 1.8 (95% CI, 1.4-2.2) for intracranial, and 1.5 (95% CI, 1.2-2.0) for nasopharyngeal bleeds. The HRs were substantially higher for cancers concordant with the bleeding site (gastrointestinal, 15.4; genitourinary, 11.8; respiratory, 10.1). Cancers were diagnosed at an earlier stage after bleeding (27.6% stage 4 after bleeding versus 31.3% without bleeding; P=0.029). CONCLUSIONS: In anticoagulated patients with AF, bleeding was strongly associated with new cancer diagnoses. Antecedent bleeding was associated with cancer diagnosis at an earlier stage. This highlights the importance of timely investigations in patients with bleeding after anticoagulation for AF, rather than attributing bleeding as an expected adverse effect.
引用
- Grewal, Wang, Austin, et al. Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study. Circulation. 2025. PMID: 39973613. doi:10.1161/CIRCULATIONAHA.124.070865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。